Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
The newspaper cutting with regard to publication of extract of unaudited financial results for the quarter ended on June 30, 2023 in Financial Express on August 12, 2023. Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link of investor call Zydus Lifesciences Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Voting results under regulation 44(3) Zydus Lifesciences Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 28th AGM Zydus Lifesciences Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Announcement of results and Scrutinizers Report Q1FY24 Quarterly Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals company Zydus Lifesciences announced Q1FY24 results: Revenue from operations at Rs 51,396 million, up 30% over last year. Research & Development (R&D;) investments for Q1FY24 stood at Rs 3,239 million (6.3% of revenues). EBITDA for Q1FY24 was Rs 15,053 million, up 81% YoY. EBITDA margin for Q1FY24 stood at 29.3% which is an improvement of 830 bps on a YoY basis. Net Profit for Q1FY24 was Rs 10,869 million, up 110% YoY. Capex (organic) for Q1FY24 was Rs 2,203 million. Dr. Sharvil Patel Managing Director, Zydus Lifesciences, said, "We are delighted to deliver strong performance during the quarter with broad based operational growth in our key businesses and a favourable product mix enhancing our profitability. Strong execution and volume offtake drove revenue ramp-up in the US, while the India branded formulations business. adjusting for NLEM impact delivered solid 12% growth. We remain reassured of achieving profitable growth aspirations for the fiscal year and thereby enhancing stakeholder value. Our persistent commitment to maintaining high-quality standards and pursuing innovation will boost our sustainable growth prospects." Result PDF Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the unaudited financial results for the quarter ended on June 30, 2023 Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2023
Unaudited Financial Results for the quarter ended on June 30, 2023 Zydus Lifesciences Ltd - 532321 - Unaudited Financial Results For The Quarter Ended On June 30, 2023
Unaudited Financial Results for the quarter ended on June 30, 2023